

In the Claims

Please cancel Claims 38, 39, 49-51, 53, 55 and 57-150, and add new Claims 151-307.

151. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.
152. (New) The antibody or antigen-binding fragment of Claim 151, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for RANTES.
153. (New) The antibody or antigen-binding fragment of Claim 151, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for MCP-3.
- But G1*
154. (New) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.
155. (New) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
156. (New) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

- Rant G7*
- Claim 11*
157. (New) The antibody or antigen-binding fragment of Claim 151, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.
158. (New) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
159. (New) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
160. (New) A composition comprising the antibody or antigen-binding fragment of Claim 151 and a physiologically acceptable vehicle or carrier.
161. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 151.
162. (New) The isolated cell of Claim 161, wherein said isolated cell is a hybridoma.
- Dar G7*
163. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:4 and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.
164. (New) The antibody or antigen-binding fragment of Claim 163, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for RANTES.

- F /
cont'd*
- list 627*
165. (New) The antibody or antigen-binding fragment of Claim 163, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for MCP-3.
 166. (New) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.
 167. (New) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
 168. (New) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
 169. (New) The antibody or antigen-binding fragment of Claim 163, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.
 170. (New) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
 171. (New) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

- A
Cont'd*
172. (New) A composition comprising the antibody or antigen-binding fragment of Claim 163 and a physiologically acceptable vehicle or carrier.
173. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 163.
174. (New) The isolated cell of Claim 173, wherein said isolated cell is a hybridoma.
175. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for eotaxin.
- Paragraph 3*
176. (New) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.
177. (New) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
178. (New) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

- Part C3*
179. (New) The antibody or antigen-binding fragment of Claim 175, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.
- Part C4*
180. (New) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
181. (New) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
182. (New) A composition comprising the antibody or antigen-binding fragment of Claim 175 and a physiologically acceptable vehicle or carrier.
183. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 175.
184. (New) The isolated cell of Claim 183, wherein said isolated cell is a hybridoma.
185. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:4 and has binding specificity for eotaxin.
186. (New) The antibody or antigen-binding fragment of Claim 185, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.

- P1
Cont'd
Rev G47*
187. (New) The antibody or antigen-binding fragment of Claim 185, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.
188. (New) The antibody or antigen-binding fragment of Claim 185, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.
189. (New) The antibody or antigen-binding fragment of Claim 185, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
190. (New) The antibody or antigen-binding fragment of Claim 185, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
191. (New) A composition comprising the antibody or antigen-binding fragment of Claim 185 and a physiologically acceptable vehicle or carrier.
192. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 185.
193. (New) The isolated cell of Claim 192, wherein said isolated cell is a hybridoma.
- Rev C57*
194. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein has at least 90% amino

F/
cont'd

acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.

- Line 65*
195. (New) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.
 196. (New) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
 197. (New) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
 198. (New) The antibody or antigen-binding fragment of Claim 194, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.
 199. (New) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
 200. (New) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

- P1
Cont'd
201. (New) A composition comprising the antibody or antigen-binding fragment of Claim 194 and a physiologically acceptable vehicle or carrier.
 202. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 194.
 203. (New) The isolated cell of Claim 202, wherein said isolated cell is a hybridoma.
 204. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:4 and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.
 205. (New) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.

Dab C4

 206. (New) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.
 207. (New) The antibody or antigen-binding fragment of Claim 204, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.

- F1
and 1d*
208. (New) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
209. (New) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
210. (New) A composition comprising the antibody or antigen-binding fragment of Claim 204 and a physiologically acceptable vehicle or carrier.
211. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 204.
212. (New) The isolated cell of Claim 211, wherein said isolated cell is a hybridoma.
- at G7*
213. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:6.
214. (New) A composition comprising the antibody or antigen-binding fragment of Claim 213 and a physiologically acceptable vehicle or carrier.
215. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 213.
216. (New) The isolated cell of Claim 215, wherein said isolated cell is a hybridoma.

- P1
Cont'd
Rev C&T
217. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein comprises the amino acid sequence of SEQ ID NO:4.
 218. (New) A composition comprising the antibody or antigen-binding fragment of Claim 217 and a physiologically acceptable vehicle or carrier.
 219. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 217.
 220. (New) The isolated cell of Claim 219, wherein said isolated cell is a hybridoma.
 221. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:5, the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.
 222. (New) The antibody or antigen-binding fragment of Claim 221, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for RANTES.
 223. (New) The antibody or antigen-binding fragment of Claim 221, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for MCP-3.

- F1
CMT '8*
224. (New) The antibody or antigen-binding fragment of Claim 221, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.
 225. (New) The antibody or antigen-binding fragment of Claim 221, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
 226. (New) The antibody or antigen-binding fragment of Claim 221, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
 227. (New) The antibody or antigen-binding fragment of Claim 221, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.
 228. (New) The antibody or antigen-binding fragment of Claim 221, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
 229. (New) The antibody or antigen-binding fragment of Claim 221, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
 230. (New) The antibody or antigen-binding fragment of Claim 221, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID

*Pl
Cntr 4*

NO:1, SEQ ID NO:5, the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.

231. (New) A composition comprising the antibody or antigen-binding fragment of Claim 221 and a physiologically acceptable vehicle or carrier.
232. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 221.
233. (New) The isolated cell of Claim 232, wherein said isolated cell is a hybridoma.
234. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:3 or the complement of SEQ ID NO:3 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.
235. (New) The antibody or antigen-binding fragment of Claim 234, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for RANTES.
236. (New) The antibody or antigen-binding fragment of Claim 234, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for MCP-3.

- F1
Cvntld*
- 237. (New) The antibody or antigen-binding fragment of Claim 234, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.
 - 238. (New) The antibody or antigen-binding fragment of Claim 234, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.
 - 239. (New) The antibody or antigen-binding fragment of Claim 234, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.
 - 240. (New) The antibody or antigen-binding fragment of Claim 234, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
 - 241. (New) The antibody or antigen-binding fragment of Claim 234, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
 - 242. (New) The antibody or antigen-binding fragment of Claim 234, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:3 or the complement of SEQ ID NO:3 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS

P/Cndd
at 65°C, and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.

243. (New) A composition comprising the antibody or antigen-binding fragment of Claim 234 and a physiologically acceptable vehicle or carrier.
244. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 234.
245. (New) The isolated cell of Claim 244, wherein said isolated cell is a hybridoma.
246. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:5, the complement of SEQ ID NO: 1 and the complement of SEQ ID NO:5 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C and has binding specificity for eotaxin.
BurG9
247. (New) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.
248. (New) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

- Dave G9*
- E/Cmt'd*
249. (New) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
250. (New) The antibody or antigen-binding fragment of Claim 246, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.
251. (New) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
252. (New) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
- Dave G10*
253. (New) The antibody or antigen-binding fragment of Claim 246, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:5, the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for eotaxin.
254. (New) A composition comprising the antibody or antigen-binding fragment of Claim 246 and a physiologically acceptable vehicle or carrier.

255. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 246.

256. (New) The isolated cell of Claim 255, wherein said isolated cell is a hybridoma.

*P1
cont'd*
257. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:3 or the complement of SEQ ID NO:3 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C and has binding specificity for eotaxin.

Refugee
258. (New) The antibody or antigen-binding fragment of Claim 257, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.

259. (New) The antibody or antigen-binding fragment of Claim 257, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.

260. (New) The antibody or antigen-binding fragment of Claim 257, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.

- Pl
Cont'd*
261. (New) The antibody or antigen-binding fragment of Claim 257, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
262. (New) The antibody or antigen-binding fragment of Claim 257, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
263. (New) The antibody or antigen-binding fragment of Claim 257, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:3 or the complement of SEQ ID NO:3 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for eotaxin.
Box G12
264. (New) A composition comprising the antibody or antigen-binding fragment of Claim 257 and a physiologically acceptable vehicle or carrier.
265. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 257.
266. (New) The isolated cell of Claim 265, wherein said isolated cell is a hybridoma.
267. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:5, the complement of SEQ ID NO:1 or the complement of
- G*

*Fi
Cmt 8*

SEQ ID NO:5, under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.

268. (New) The antibody or antigen-binding fragment of Claim 267, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for MCP-2.
269. (New) The antibody or antigen-binding fragment of Claim 267, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for MCP-4.
270. (New) The antibody or antigen-binding fragment of Claim 267, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.
271. (New) The antibody or antigen-binding fragment of Claim 267, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
272. (New) The antibody or antigen-binding fragment of Claim 267, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
273. (New) The antibody or antigen-binding fragment of Claim 267, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.

- F/Cord's*
- 274. (New) The antibody or antigen-binding fragment of Claim 267, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
 - 275. (New) The antibody or antigen-binding fragment of Claim 267, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
 - 276. (New) The antibody or antigen-binding fragment of Claim 267, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:5, the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.
 - 277. (New) A composition comprising the antibody or antigen-binding fragment of Claim 267 and a physiologically acceptable vehicle or carrier.
 - 278. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 267.
 - 279. (New) The isolated cell of Claim 278, wherein said isolated cell is a hybridoma.
 - 280. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence

*P /
Contd*

of SEQ ID NO:3 or the complement of SEQ ID NO:3 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.

281. (New) The antibody or antigen-binding fragment of Claim 280, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for MCP-2.
282. (New) The antibody or antigen-binding fragment of Claim 280, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for MCP-4.
283. (New) The antibody or antigen-binding fragment of Claim 280, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.
284. (New) The antibody or antigen-binding fragment of Claim 280, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.
285. (New) The antibody or antigen-binding fragment of Claim 280, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.
286. (New) The antibody or antigen-binding fragment of Claim 280, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.

- f1
Cont'd*
287. (New) The antibody or antigen-binding fragment of Claim 280, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
288. (New) The antibody or antigen-binding fragment of Claim 280, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:3 or the complement of SEQ ID NO:3 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.
289. (New) A composition comprising the antibody or antigen-binding fragment of Claim 280 and a physiologically acceptable vehicle or carrier.
290. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 280.
291. (New) The isolated cell of Claim 290, wherein said isolated cell is a hybridoma.
- Line 613*
292. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by SEQ ID NO:1 or SEQ ID NO:5.
293. (New) A composition comprising the antibody or antigen-binding fragment of Claim 292 and a physiologically acceptable vehicle or carrier.

294. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 292.

295. (New) The isolated cell of Claim 294, wherein said isolated cell is a hybridoma.

296. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by SEQ ID NO:3.

Antibody 7B11

297. (New) A composition comprising the antibody or antigen-binding fragment of Claim 296 and a physiologically acceptable vehicle or carrier.

298. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 296.

299. (New) The isolated cell of Claim 298, wherein said isolated cell is a hybridoma.

300. (New) Antibody 7B11 (ATCC Accession No. HB-12195) or an antigen binding fragment thereof.

Antibody 7B11

301. (New) A composition comprising the antibody or antigen-binding fragment of Claim 300 and a physiologically acceptable vehicle or carrier.

302. (New) The hybridoma cell line deposited under ATCC Accession No. HB-12195.

303. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3, wherein said antibody or antigen-binding fragment comprises the light chain CDRs (CDR1, CDR2 and CDR3) and

Antibody 7B11